Process for making dry and stable hemostatic compositions
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61P-007/04
A61L-024/10
A61K-038/48
출원번호
US-0150809
(2011-06-01)
등록번호
US-9408945
(2016-08-09)
발명자
/ 주소
Goessl, Andreas
Osawa, Atsushi Edward
Reich, Cary J.
출원인 / 주소
Baxter International Inc.
대리인 / 주소
Kilpatrick Townsend & Stockton LLP
인용정보
피인용 횟수 :
0인용 특허 :
130
초록▼
Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent,b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in h
Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent,b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis,c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container,d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, ande) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
대표청구항▼
1. A process for making a dry and stable hemostatic composition, said process comprising: a) providing a first component comprising a solution of a coagulation inducing agent;b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis;c) mix
1. A process for making a dry and stable hemostatic composition, said process comprising: a) providing a first component comprising a solution of a coagulation inducing agent;b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis;c) mixing said first component and said second component under conditions effective to form a wet paste while preventing degradation of the second component by said first component in a final container or mixing said first component and said second component under conditions effective to form the wet paste while preventing degradation of the second component by said first component and transferring said wet paste into a final container, wherein the wet paste is without a free liquid phase;d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form; ande) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a finished dry and stable hemostatic composition, wherein:the first component comprises thrombin,the mixing step comprises mixing the first component and the second component at a temperature within a range from about 2° C. to about 15° C., anda contact time between the first component and the second component in the wet paste before lyophilizing is within a range from five minutes to six hours,85% (weight/weight) or less of the wet paste is the solution of the coagulation inducing agent,the finishing step comprises sterilizing the dry and stable hemostatic composition in said final container,said thrombin has an initial activity prior to the lyophilizing step, andsaid finished dry and stable hemostatic composition has the capability to retain at least 90% of said thrombin activity after 24 months storage in dry form at room temperature. 2. The process according to claim 1, wherein step c) is performed under aseptic conditions. 3. The process according to claim 1, wherein step c) is performed by extrusion. 4. The process according to claim 1, wherein step d) comprises an ethylene oxide sterilization step of application of an ionizing irradiation. 5. The process according to claim 1, wherein said first component contains thrombin in a CaCl2 solution. 6. The process according to claim 1, wherein said first component contains thrombin in a concentration of 10 to 10,000 I.U./ml. 7. The process according to claim 1, wherein a syringe is used as said final container. 8. The process according to claim 7, wherein said syringe is a syringe finished together with a diluent syringe with a pharmaceutically acceptable diluent for reconstituting said dry and stable hemostatic composition. 9. The process according to claim 1, wherein said first component comprises human thrombin. 10. The process according to claim 1, wherein said first component comprises recombinant human thrombin. 11. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis contains a protein selected from the group consisting of gelatin, soluble collagen, albumin, hemoglobin, fibrinogen, fibrin, casein, fibronectin, elastin, keratin, and laminin, and derivatives or combinations thereof. 12. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis contains a polysaccharide selected from the group consisting of glycosaminoglycans, starch derivatives, cellulose derivatives, hemicellulose derivatives, xylan, agarose, alginate, and chitosan, and derivatives or combinations thereof. 13. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis contains a polymer selected from the group consisting of polyacrylates, polymethacrylates, polyacrylamides, polyvinyl resins, polylactide-glycolides, polcaprolactones, polyoxyethlenes, and derivatives and combinations thereof. 14. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis contains a crosslinked polysaccharide, a crosslinked protein, a crosslinked non-biologic polymer, or mixtures thereof. 15. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis is a granular material. 16. The process according to claim 1, wherein said biocompatible polymer suitable for use in hemostasis is a cross-linked gelatin. 17. The process according to claim 1, wherein said final container further contains an amount of a stabilizer effective to inhibit modification of the polymer when exposed to sterilizing radiation, wherein the stabilizer is selected from the group consisting of ascorbic acid, sodium ascorbate, other salts of ascorbic acid, and an antioxidant. 18. The process according to claim 1, wherein the mixing step comprises mixing the first component and the second component at a temperature of about 4° C. 19. The process according to claim 1, wherein the mixing step comprises mixing the first component and the second component at a temperature within a range from about 2° C. to about 10° C. 20. The process according to claim 1, wherein the mixing step comprises mixing the first component and the second component at a temperature within a range from about 2° C. to about 6° C. 21. The process according to claim 1, wherein the mixing step comprises mixing the first component and the second component at a temperature of about 6° C. 22. The process according to claim 1, wherein the contact time between the first component and the second component during the mixing and before the lyophilization is within a range from five minutes to two hours. 23. The process according to claim 1, wherein the contact time between the first component and the second component during the mixing and before the lyophilization is within a range from five minutes to 30 minutes. 24. The process according to claim 1, wherein the dry and stable hemostatic composition has a moisture content from 0.5% to 5%. 25. The process according to claim 1, wherein less than 80% (weight/weight) of the wet paste is the solution of the coagulation inducing agent. 26. The process according to claim 1, further comprising sterilizing said first component and sterilizing said second component before mixing. 27. The process according to claim 1, wherein step e) comprises compacting the dry and stable composition. 28. The process according to claim 1, wherein step c) comprises gradually dropping the second component into a constantly stirred solution of the coagulation inducing agent. 29. The process according to claim 1, wherein step c) comprises simultaneously feeding the second component and the first component into an extrusion machine wherein the first component and the second component are blended into the wet paste. 30. The process according to claim 1, wherein the finished dry and stable hemostatic composition contains 500 to 5,000 I.U. thrombin. 31. The process according to claim 1, wherein the finished dry and stable hemostatic composition contains 50 to 5,000 I.U. thrombin. 32. The process according to claim 1, wherein the finished dry and stable hemostatic composition contains 100 to 1,000 I.U. thrombin. 33. The process according to claim 1, wherein said first component contains thrombin in a concentration of 500 I.U./ml. 34. The process according to claim 33, wherein said thrombin has a concentration of 450 IU./ml or more after reconstitution of the finished dry and stable hemostatic composition after 24 months storage in dry form at room temperature. 35. The process according to claim 1, wherein said finished dry and stable hemostatic composition has the capability to retain at least 95% of said thrombin activity after said 24 months storage. 36. The process according to claim 1, wherein 60% to 80% (weight/weight) of the wet paste is the solution of the coagulation inducing agent. 37. The process according to claim 1, wherein step c) comprises mixing said first component and said second component in the final container. 38. The process according to claim 1, wherein step c) comprises transferring said wet paste into the final container. 39. The process according to claim 38, wherein transferring said wet paste into the final container comprises extruding said wet paste into the final container. 40. The process according to claim 38, wherein step c) comprises repeated transferring of said first component and said second component between two syringes. 41. The process according to claim 1, wherein step d) comprises sterilizing with an ionizing radiation. 42. The process according to claim 1, wherein step d) comprises an ethylene oxide sterilization step.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (130)
Kowanko Nicholas (618 S. Fifth St. Moorhead MN 56560), Adhesive composition and method.
Yeung Jeffrey E. (San Jose CA) Chu George H. (Cupertino CA) DeLustro Frank A. (Belmont CA) Rhee Woonza M. (Palo Alto CA), Anti-adhesion films and compositions for medical use.
Tay Sew-Wah (Plymouth MN) Schankereli Kemal (Stillwater MN) Holman Thomas (Minneapolis MN) Mische Hans (St. Cloud MN), Apparatus and method for sealing vascular punctures.
Tardy Michel (Lyons FRX) Tiollier Jerome (Lyons FRX) Tayot Jean-Louis (La Tour De Salvagny FRX), Biocompatible bioresorbable and non-toxic adhesive composition for surgical use.
Epstein Gordon H. ; Lempert Todd E. ; Martin Brian B., Biological sealant mixture and system for use in percutaneous occlusion of puncture sites and tracts in the human body and method.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Miyata Teruo (Tokyo NJ JPX) Rubin Albert L. (Englewood NJ) Stenzel Kurt H. (Englewood NJ) Dunn Michael W. (New Rochelle NY), Collagen drug delivery device.
Rhee Woonza M. (Palo Alto CA) Rao Prema R. (Los Gatos CA) Chu George H. (Cupertino CA) DeLustro Frank A. (Belmont CA) Harner Carol F. H. (Redwood Shores CA) Sakai Naomi (San Mateo CA) Schroeder Jacqu, Collagen-based bioadhesive compositions.
Silver Fred (Bangor PA) Sharma Vinay (Long Valley NJ) Berndt Dieter R. (Allenwood NJ) Marn Louis E. (Morris Plains NJ), Collagen-based wound dressing and method for applying same.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Henry Raymond L. (Grosse Pointe Woods MI), Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers an.
Palefsky Howard (Atherton CA) Pharriss Bruce B. (Palo Alto CA) Chu George (Cupertino CA), Composition of low type III content human placental collagen.
Olof Mikael Trollsas ; Donald G. Wallace ; Frank A. DeLustro, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use.
Prior Jeffrey J. ; Wallace Donald G. ; Sierra David H. ; DeLustro Frank A., Compositions containing thrombin and microfibrillar nanometer collagen, and methods for preparation and use thereof.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Dexter MI) Levinson Robert S. (Chesterfield MO), Drug delivery by injection with thermoreversible gels containing polyoxyalkylene copolymers.
Qian, Zhen; Osawa, A. Edward; Reich, Cary J.; Wallace, Donald G.; Shargill, Narinder S.; Vega, Felix, Dry hemostatic compositions and methods for their preparation.
Narotam Pradeep K.,CAX ; van Dellen James R.,ZAX ; O'Fee Robert P. ; McKinney ; III George W. ; Archibald Simon J. ; O'Grady Judith, Dural/meningeal repair product using collagen matrix.
Wallace Donald G. (Menlo Park CA) McMullin Hugh (Pacifica CA) Chu George (Cupertino CA), Injectable ceramic compositions and methods for their preparation and use.
Wallace Donald G. (Menlo Park) McMullin Hugh (Pacifica) Chu George (Cupertino CA), Injectable ceramic compositions and methods for their preparation and use.
Wallace Donald G. (Menlo Park CA) Reihanian Hertsel (San Francisco CA) Pharriss Bruce B. (Palo Alto CA) Braun William G. (Los Altos CA), Injectable implant composition having improved intrudability.
Rhee Woonza M. ; Berg Richard A. ; Chu George H. ; DeLustro Frank A. ; Jolivette Dan M. ; McCullough Kimberly A., Injectable or implantable biomaterials for filling or blocking lumens and voids of the body.
Etienne Schacht BE; An Van Den Bulcke BE; Bernard Delaey BE; Jean-Pierre Draye BE, Medicaments based on polymers composed of methacrylamide-modified gelatin.
Wahlig Helmut (Darmstadt DEX) Dingeldain Elvira (Dreieich DEX) Braun Dietrich (Darmstadt-Arheilgen DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Wahlig Helmut (Darmstadt DEX) Dingeldein Elvira (Dreieich DEX) Braun Dietrich (Darmstadt DEX), Medicinally useful, shaped mass of collagen resorbable in the body.
Goldberg Eugene P. (Gainesville FL) Yaacobi Yoseph (Gainesville FL), Method and composition for preventing surgical adhesions using a dilute solution of polymer.
Eibl Johann (Vienna ATX) Schwarz Otto (Vienna ATX) Elsinger Fritz (Vienna ATX) Wber Gnter (Oberwaltersdorf ATX) Philapitsch Anton (Ebenfurt ATX) Linnau Yendra (Vienna ATX) Dorner Friedrich (Vienna AT, Method of inactivating reproducible filterable pathogens in blood products as well as a method of producing blood produc.
Sawyer Philip N. (Brooklyn NY) Sawyer Philip M. (Menlo Park CA) Reich Cary J. (Laguna Hills CA), Methods for sealing of staples and other fasteners in tissue.
Song Suk-Zu (Moorpark CA) Morawiecki Andrew (Camarillo CA) Pierce Glenn F. (Thousand Oaks CA) Pitt Colin G. (Westlake Village CA), Multi-layered collagen film compositions for delivery of proteins and methods of using same.
Saferstein Lowell (Edison NJ) Wolf Stephen (Neshanic Station NJ) Kamp Lola (Highland Park NJ) Linsky Cary (East Brunswick NJ) Wiseman David (Highland Park NJ), Process for preparing a neutralized oxidized cellulose product and its method of use.
Sharma Vinay K. (12 Walnut Dr. Long Valley NJ 07853), Process of preparing microparticulate collagen, collagen-based products thereby and method of applying same.
Wallace Donald G. ; Cruise Gregory M. ; Rhee Woonza M. ; Schroeder Jacqueline Anne ; Coker ; III George T. ; Maroney Marcee M., Rapid gelling biocompatible polymer composition.
Wallace, Donald G.; Cruise, Gregory M.; Rhee, Woonza M.; Schroeder, Jacqueline Anne; Coker, III, George T.; Maroney, Marcee M.; Trollsas, Olof Mikael, Rapid-gelling biocompatible polymer composition and associated methods of preparation and use.
Kensey Kenneth (Chester Springs PA) Nash John E. (Downington PA) Evans Douglas (Devon PA), System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating.
Bass Lawrence S. (Little Neck NY) Libutti Steven K. (Fort Lee NJ) Eaton Alexander M. (Durham NC), Tissue bonding and sealing composition and method of using the same.
Bass Lawrence S. (Little Neck NY) Libutti Steven K. (Lido Beach NY) Eaton Alexander M. (New York NY), Tissue bonding and sealing composition and method of using the same.
Hermes Matthew E. (Easton CT) Muth Ross R. (Brookfield CT) Gustafson Darel L. (Shelton CT), Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin.
Weldon Thomas D. (P.O. Box 5149 Aquadilla PR 00605) Larsen Charles E. (P.O. Box 5149 Aquadilla PR 00605), Wound treating device using an inflatable membrane and method for treating wounds.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.